For whom the bellwether tolls

British Biotech (LSE:BBG; BBIOY) slipped towards a three-year low when it touched 48.75p on Monday. The slump was a reaction to the news that BBG had sacked Andrew Millar, its director of clinical research, who has been more than willing to talk to some members of the British press about the company.

Among the revelations disclosed in interviews by Millar is an allegation that the U.S. Securities and Exchange Commission is investigating the company. Millar, who already was under suspension for undisclosed violations of company policies (see BioCentury, March 16), was terminated on Monday...